233 related articles for article (PubMed ID: 10998335)
21. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis.
Fisher KJ; Choi H; Burda J; Chen SJ; Wilson JM
Virology; 1996 Mar; 217(1):11-22. PubMed ID: 8599194
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of adenoviral vectors by flow cytometry.
Weaver LS; Kadan MJ
Methods; 2000 Jul; 21(3):297-312. PubMed ID: 10873484
[TBL] [Abstract][Full Text] [Related]
23. Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector.
Wang Q; Greenburg G; Bunch D; Farson D; Finer MH
Gene Ther; 1997 May; 4(5):393-400. PubMed ID: 9274715
[TBL] [Abstract][Full Text] [Related]
24. Development of a FLP/frt system for generating helper-dependent adenoviral vectors.
Ng P; Beauchamp C; Evelegh C; Parks R; Graham FL
Mol Ther; 2001 May; 3(5 Pt 1):809-15. PubMed ID: 11356086
[TBL] [Abstract][Full Text] [Related]
25. Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: comparison of promoter activities.
Sakurai F; Kawabata K; Yamaguchi T; Hayakawa T; Mizuguchi H
Gene Ther; 2005 Oct; 12(19):1424-33. PubMed ID: 15944730
[TBL] [Abstract][Full Text] [Related]
26. Production of lentiviral vectors by transient expression of minimal packaging genes from recombinant adenoviruses.
Kuate S; Stefanou D; Hoffmann D; Wildner O; Uberla K
J Gene Med; 2004 Nov; 6(11):1197-205. PubMed ID: 15459964
[TBL] [Abstract][Full Text] [Related]
27. Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector.
Van Linthout S; Lusky M; Collen D; De Geest B
Gene Ther; 2002 Nov; 9(22):1520-8. PubMed ID: 12407424
[TBL] [Abstract][Full Text] [Related]
28. A convenient plasmid system for construction of helper-dependent adenoviral vectors and its application for analysis of the breast-cancer-specific mammaglobin promoter.
Shi CX; Graham FL; Hitt MM
J Gene Med; 2006 Apr; 8(4):442-51. PubMed ID: 16389604
[TBL] [Abstract][Full Text] [Related]
29. Complementation of a human adenovirus early region 4 deletion mutant in 293 cells using adenovirus-polylysine-DNA complexes.
Scaria A; Curiel DT; Kay MA
Gene Ther; 1995 Jun; 2(4):295-8. PubMed ID: 7552990
[TBL] [Abstract][Full Text] [Related]
30. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector.
Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B
J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055
[TBL] [Abstract][Full Text] [Related]
31. Development of a packaging cell line for propagation of replication-deficient adenovirus vector.
Kim JS; Lee SH; Cho YS; Park K; Kim YH; Lee JH
Exp Mol Med; 2001 Sep; 33(3):145-9. PubMed ID: 11642550
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of adenovirus cytotoxicity, replication, and E2a gene expression by adeno-associated virus.
Jing XJ; Kalman-Maltese V; Cao X; Yang Q; Trempe JP
Virology; 2001 Dec; 291(1):140-51. PubMed ID: 11878883
[TBL] [Abstract][Full Text] [Related]
33. A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing, helper-dependent E1-positive particles.
Murakami P; Pungor E; Files J; Do L; van Rijnsoever R; Vogels R; Bout A; McCaman M
Hum Gene Ther; 2002 May; 13(8):909-20. PubMed ID: 12031124
[TBL] [Abstract][Full Text] [Related]
34. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors.
Morral N; O'Neal W; Zhou H; Langston C; Beaudet A
Hum Gene Ther; 1997 Jul; 8(10):1275-86. PubMed ID: 9215744
[TBL] [Abstract][Full Text] [Related]
35. Insulated hsp70B' promoter: stringent heat-inducible activity in replication-deficient, but not replication-competent adenoviruses.
Rohmer S; Mainka A; Knippertz I; Hesse A; Nettelbeck DM
J Gene Med; 2008 Apr; 10(4):340-54. PubMed ID: 18265421
[TBL] [Abstract][Full Text] [Related]
36. Development of a recombinant adenovirus vector production system free of replication-competent adenovirus by utilizing a packaging size limit of the viral genome.
Suzuki T; Sasaki T; Yano K; Sakurai F; Kawabata K; Kondoh M; Hayakawa T; Yagi K; Mizuguchi H
Virus Res; 2011 Jun; 158(1-2):154-60. PubMed ID: 21470569
[TBL] [Abstract][Full Text] [Related]
37. Gutted adenoviral vector growth using E1/E2b/E3-deleted helper viruses.
Barjot C; Hartigan-O'Connor D; Salvatori G; Scott JM; Chamberlain JS
J Gene Med; 2002; 4(5):480-9. PubMed ID: 12221641
[TBL] [Abstract][Full Text] [Related]
38. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors.
Mizuguchi H; Kay MA
Hum Gene Ther; 1999 Aug; 10(12):2013-7. PubMed ID: 10466635
[TBL] [Abstract][Full Text] [Related]
39. Protease-deleted adenovirus vectors and complementing cell lines: potential applications of single-round replication mutants for vaccination and gene therapy.
Oualikene W; Lamoureux L; Weber JM; Massie B
Hum Gene Ther; 2000 Jun; 11(9):1341-53. PubMed ID: 10890743
[TBL] [Abstract][Full Text] [Related]
40. Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: implications for gene therapy.
Amalfitano A; Chamberlain JS
Gene Ther; 1997 Mar; 4(3):258-63. PubMed ID: 9135740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
